Related Experiment Videos
Inflammatory markers and coronary interventions: a potentially useful follow-up modality after stenting
Giuseppe Patti1, Germano Di Sciascio, Andrea D'Ambrosio
1Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy.
Insights
Six months after coronary stenting, inflammatory markers like interleukin-1 receptor antagonist (IL-1Ra) and C-reactive protein (CRP) significantly decreased in patients with unstable angina, suggesting improved prognosis.
Area of Science:
- Cardiology
- Inflammation Biology
- Biomarkers
Background:
- Periprocedural inflammatory markers influence prognosis after percutaneous coronary interventions.
- Long-term changes in interleukin-1 receptor antagonist (IL-1Ra) and C-reactive protein (CRP) post-coronary intervention are not well-studied.
Purpose of the Study:
- To assess serial changes in IL-1Ra and CRP levels before and after coronary stenting.
- To correlate these inflammatory marker variations with clinical status during follow-up.
Main Methods:
- Serial plasma IL-1Ra and CRP measurements at baseline, 3, and 6 months post-stent implantation.
- Study included 31 patients with symptomatic coronary artery disease and no ischemia at 6-month follow-up.
Main Results:
- No significant IL-1Ra or CRP changes at 3 months.
- Significant reduction in both IL-1Ra and CRP observed at 6 months post-procedure (P=0.048 and P=0.017, respectively).
- Reduction was significant in unstable angina patients but not in stable angina patients.
Conclusions:
- A significant decrease in IL-1Ra and CRP levels occurs 6 months post-stenting in patients with preprocedural unstable angina who remain ischemia-free.
- This reduction indicates potential inflammatory process stabilization.
- May be linked to a favorable prognosis following coronary interventions.
Abstract:
Periprocedural levels of various inflammatory markers have been correlated with prognosis in patients undergoing percutaneous coronary interventions. However, long-term variations of interleukin-1 receptor antagonist (IL-1Ra) or C-reactive protein (CRP) during follow-up after coronary interventions were not previously investigated. The aim of our study was to perform serial evaluations of these markers before and after coronary stenting and to correlate them with clinical status. Plasma levels of IL-1Ra and CRP were measured at baseline and 3 and 6 months after the procedure in 31 patients with symptomatic coronary artery disease undergoing stent implantation, who had no evidence of myocardial ischemia at 6-month follow-up. While at 3 months there were no significant variations of baseline values, 6 months after the procedure a significant decrease from baseline was observed both in IL-1Ra and CRP levels (median -24 pg/ml, P = 0.048, and -0.13 mg/dl, P = 0.017, respectively). Six-month reduction in both IL-1Ra and CRP levels was significant in patients with unstable angina (n = 18; IL-1Ra: from 175 to 119 pg/ml, P = 0.001; CRP: from 0.52 to 0.18 mg/dl, P = 0.002) and nonsignificant in those with stable angina (n = 13) on admission (IL-1Ra: from 123 to 158 pg/ml, P = 0.22; CRP: from 0.19 to 0.10 mg/dl, P = 0.44). In conclusion, a significant reduction of IL-1Ra and CRP levels is observed 6 months after stent implantation in patients with preprocedural unstable angina who remain free of ischemia. This decrease suggests a stabilization of the inflammatory process and may be associated with a favorable prognosis after coronary interventions.